To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Tobi Remains Effective In CF Patients After 11 Months URL: http://www.pslgroup.com/dg/86A2E.htm Doctor's Guide June 16, 1998
BERLIN, GERMANY -- June 16, 1998 -- Longer-term interim data on PathoGenesis Corp.'s Tobi(R) (tobramycin solution for inhalation) showed that cystic fibrosis patients who had been on Tobi for 11 months maintained a level of improvement in lung function similar to that achieved at the end of the six-month Phase III clinical trials. The results were presented today at a satellite meeting of the 22nd European Cystic Fibrosis Conference, sponsored by the University Children's Hospital, Charite, Berlin. Interim data on patients who had been on placebo and began taking Tobi after the conclusion of the Phase III clinical trials showed initial lung function improvement similar to what was seen in the Phase III clinical trials. "I am very encouraged that the clinical improvement seen in the six-month trials has been maintained," said Dr. Bonnie Ramsey, M.D., professor of pediatrics at the University of Washington, Seattle. and principal investigator for the Tobi clinical trials. In addition, 18-month Tobi data are expected to be presented at the North American Cystic Fibrosis Conference, Oct. 15-18, 1998. Each ready-to-use ampule of Tobi contains 300 milligrams of tobramycin in a 5 millilitre solution. It is inhaled twice daily and requires about 15 minutes per treatment. The Tobi treatment regimen consists of repeated cycles of 28 days on drug, followed by 28 days off drug. More information on: Tobi, PathoGenesis Corp. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.